Tuesday, January 27, 2026 1/27/2026

Exploring the Neuroprotective Potential of CBD in Preventing Oxaliplatin-Induced Neuropathy: A Prospective Study

Award Number: R21CA292276
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2025
PERIOD OF PERFORMANCE END DATE: 07/31/2027

Group Awards By:

View Award Description

Exploring the Neuroprotective Potential of CBD in Preventing Oxaliplatin-Induced Neuropathy: A Prospective Study - Project Summary The project titled “Exploring the Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy: A Prospective Study” will evaluate the feasibility of a hemp-based cannabinoid (CBD) related intervention in colorectal cancer (CRC) patients undergoing oxaliplatin based chemotherapy and generate preliminary data on its ability to provide potential neuroprotective benefits and reduce/prevent incidence of chemotherapy-induced neuropathy (CIPN). Additionally, we will also be exploring the expression of inflammatory markers and miRNA in oxaliplatin treated patients and comparing between the groups that received a CBD intervention versus those who did not to understand the biological rationale of the neuroprotective effect of CBD. In aim 1, we will investigate the feasibility and acceptability of incorporating hemp-based CBD supplementation as a supportive therapy during Ox-based chemotherapy for CRC patients. We will also study the rates of acute and chronic Ox induced Peripheral Neuropathy (OIPN) and other treatment related adverse events in patients treated with Hemp based CBD and Ox based chemotherapy and compare them to rates seen among patients who get standard therapy. In aim 2, we will determine differentially expressed inflammatory markers and miRNA in patients treated with Ox with or without CBD treatment. To conduct this work, we assembled a team with expertise in clinical and basic science of colorectal cancer and cannabinoid research with a strong record of accomplishment of collaborations and innovations. Our study will pave the way for larger randomized trials that will aid in understanding the potential benefits of CBD supplementation in managing OIPN and associated adverse effects.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $429,162 )
2025	2025	THE INSTITUTE FOR CANCER RESEARCH	333 COTTMAN AVE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Cancer Treatment Research	000	1	7/30/2025	NEW	$429,162
														Subtotal = $429,162

Grand Total All Awards = $429,162

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Exploring the Neuroprotective Potential of CBD in Preventing Oxaliplatin-Induced Neuropathy: A Prospective Study

Award Number: R21CA292276

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2025

PERIOD OF PERFORMANCE END DATE: 07/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer